What is Stem Cell: [StemCells] Advance Cell makes 140 cell types from hES

Thursday, April 3, 2008

[StemCells] Advance Cell makes 140 cell types from hES

Advanced Cell Technology Platform Yields Over 140 Cell Types from
Human Embryonic Stem Cells
April 2, 2008

Research Represents a Breakthrough in the Mapping and
Characterization of the Cells of Early Human Development; Company to
provide differentiated embryonic progenitor cell lines from its
ACTCellerate Platform for therapeutic applications, research tools,
and drug discovery

ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc.
(OTCBB: ACTC; www.advancedcell.com) reported today on a large-scale
differentiation process that has generated panels of differentiating
human progenitor cell lines from human embryonic stem cells (hESCs).
The research will be published in the April issue of Regenerative
Medicine (Vol. 3[3] e-pub ahead of print) and will be freely
available at www.futuremedicine.com/loi/rme.

Since the first isolation of hESCs, scientists and industry alike
have been working to harness the power of these cells for the purpose
of restoring and regenerating body systems that have been damaged by
disease or injury

One of the hurdles has been a commercially viable means for the
expansion of sufficient numbers of the cell types needed for tissue
regeneration. With the publication of work entitled "The ACTCellerate
Initiative: large-scale combinatorial cloning of novel human
embryonic stem cell derivatives," ACT scientists have solved some of
these problems. The paper describes a system that was established to
isolate and clonally expand tissue specific precursors that
heretofore could only be isolated from aborted human fetal tissue.

Dr Chris Mason (UCL), Associate Editor of Regenerative Medicine
said, "This is an enormously exciting development for the regen
sector. The research reported… represents a quantum leap forward in
embryonics, the mapping and characterization of the cells of early
human development. Without any doubt, the ACTCellerate technology
will greatly hasten the translation of human embryonic stem cell-
based therapies into safe and effective products for routine clinical
practice."

The benefits of the ACTCellerate technology transcend therapeutics
and extend as well into revolutionary applications for drug
discovery, drug toxicity testing, and cancer research. This advance
holds great promise for future research and may one day lead to many
new cell-based therapies in the emerging field of regenerative
medicine.

Another important finding in this publication is that these normal
embryonic progenitor cell types show the expression of certain genes
(such as oncofetal markers) often associated in the literature with
malignant cancer. However, when these progenitor cells were injected
into supportive mice, no malignant tumors could be observed. This
indicates that expression of such genes is a function of these cells'
normal primitive stage of differentiation and not linked to any
disease potential.

William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology,
Inc., stated, "We are greatly indebted to Mike West for his insight
in initiating this program during his tenure with ACT and to the
entire ACT scientific team for their perseverance in bringing this
groundbreaking research to the conclusions described in this
publication. ACT has taken great strides in identifying both clinical
applications for this approach as well as for the ACTCellerate cell
line library for drug target discovery, assay development, and direct
therapeutics development across a wide spectrum of clinical
indications. We are now in a position to offer our refined technology
and know-how to potential partners and licensees."

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying
cellular technology in the emerging field of regenerative medicine.
The company operates facilities in California and Massachusetts.

For more information, visit www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and
operating results, future growth in research and development
programs, potential applications of our technology, opportunities for
the company and any other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements that
are not statements of historical fact (including statements
containing the
words "will," "believes," "plans," "anticipates," "expects," "estimate
s," and similar expressions) should also be considered to be forward-
looking statements. There are a number of important factors that
could cause actual results or events to differ materially from those
indicated by such forward-looking statements, including: limited
operating history, need for future capital, risks inherent in the
development and commercialization of potential products, protection
of our intellectual property, and economic conditions generally.
Additional information on potential factors that could affect our
results and other risks and uncertainties are detailed from time to
time in the company's periodic reports, including the report on Form
10-QSB for the quarter ended September 30, 2007. Forward-looking
statements are based on the beliefs, opinions, and expectations of
the company's management at the time they are made, and the company
does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and
expectations of the company's management at the time they are made,
and the company does not assume any obligation to update its forward-
looking statements if those beliefs, opinions, expectations, or other
circumstances should change.

Contacts
Media:
Chad Griffin Consulting, Inc.
Jordan Markwith, 310-888-3523
or
Investors:
CEOcast, Inc.
Daniel Schustack, 212-732-4300

http://www.businesswire.com/portal/site/google/?
ndmViewId=news_view&newsId=20080403005502&newsLang=en

__._,_.___

Messages in this topic (1) Reply (via web post) | Start a new topic

Messages

____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:

Children's Neurobiological Solutions
http://www.CNSfoundation.org/

Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123

The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯